الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 117 |  |  |
| | | from | 117 | | |
Abstract
Chronic myeloid leukemia (CML) represents 15% of adult leukemias. Imatinib Mesylate (IM) is the gold standard drug for new cases of CML. Treatment with imatinib resulted in improvement of the majority of cases. The drug acts as a BCR-ABL tyrosine kinase inhibitor. Despite the success achieved by IM in the treatment of the disease, a considerable percentage (about 25%) of cases may develop resistance to the drug.
MicroRNAs, are small (~22 nucleotides) single-stranded folded into a hairpin structure, non-coding RNAs that regulate gene expression. Some micro-RNAs were shown to have a major role in controlling cellular autophagy.
In this work we studied the association between microRNA 30a (miR-30a) and Beclin 1 mediated autophagy and the response to IM in Egyptian CML patients.
In order to achieve this goal, the study included newly diagnosed (group I, n=20), IM responder (group II, n=30), IM resistant (group III, n=30) CML patients and a healthy control group of matched age and sex (group IV, n=20).
miR-30a expression was assayed by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). The fold change for miR-30a between CML cases and healthy controls was calculated using relative quantification method (2-ΔΔCT). Beclin 1 expression was assayed in Peripheral blood mononuclear cells (PBMCs) by western blotting.